J-Pharma, European Biotech Firm Sign Term Sheet to Develop, Commercialize Neuro-Inflammatory Drug; Shares Decline 7%
MT Newswires Live
Sep 25
J-Pharma (TYO:520A) signed a non-binding term sheet with a European biotechnology firm for the development and commercialization of JPH034, a LAT1 inhibitor under development by the company that targets neuro-inflammatory diseases, according to a Friday filing on the Tokyo Stock Exchange.
Under the non-binding term sheet, J-Pharma will license development and commercialization rights for JPH034 globally, excluding Japan, South Korea, Taiwan, and the Association of Southeast Asian Nations (ASEAN) member states, it said.
Shares of J-Pharma fell nearly 7% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.